ALNYLAM PHARMACEUTICALS, INC. — Form 10-Q
Filed October 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 12/100
What the filing says
Yvonne L. Greenstreet (CEO) and Jeffrey V. Poulton (CFO) certified the Form 10-Q for the quarter ended September 30, 2026, dated October 29, 2026. Both officers affirmed that disclosure controls and internal financial reporting controls are effective, no material weaknesses or fraud were identified, and financial statements fairly present the company's condition and operations.
Why this rating
Routine SEC-required officer certifications with no material content changes, deficiencies, or transactions disclosed. Boilerplate compliance filing.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.